April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
I had to double check that it really was earlier this year that bictegravir was U.S. Food and Drug Administration-approved. On Feb. 7, the approval of the fixed-dose formulation of bictegravir with tenofovir alafenamide fumarate and emtricitabine (Bi...
After 48 weeks a study found that Biktarvy was similarly effective and well tolerated as women's other regimens and rates of side effects were relatively low.
On March 28, the Department of Health and Human Services Guidelines issued an update to the HIV treatment guidelines, with a focus on the recent approval of bictegravir/TAF/FTC.
Reports about bictegravir, the most recently approved integrase inhibitor, were included in an oral presentation and in several posters at CROI 2018.
Brand Name: Biktarvy Other Names: BIC/FTC/TAF, bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate Drug Class: Combination Drugs
On Feb. 7, 2018, the U.S. FDA approved a new fixed-dose combination (FDC) containing bictegravir, emtricitabine and tenofovir alafenamide (TAF).